VISIBLE COHORT A: GUSELKUMAB DEMONSTRATED SKIN CLEARANCE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE THROUGH WEEK 48 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS ACROSS ALL SKIN TONES

Andrew Alexis,[1] Adrian O. Rodriguez,[2] Geeta Yadav,[3,4] Stephen K. Tyring,[5] Olivia Choi,[6] Theodore Alkousakis,[6] Daphne Chan,[6] Tony Ma,[7] Maxwell Sauder,[3,8] Javier Alonso-Llamazares,[9] Seemal R. Desai[10,11]

[1]Weill Cornell Medicine, New York, NY, USA; [2]Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA; [3]University of Toronto, Toronto, ON, Canada; [4]FACET Dermatology, Toronto, ON, Canada; [5]Center for Clinical Studies, Webster, TX, USA; [6]Johnson & Johnson, Horsham, PA, USA; [7]Johnson & Johnson, Spring House, PA, USA; [8]Probity Medical Research, Waterloo, ON, Canada; [9]Driven Research LLC, Coral Gables, FL, USA; [10]Innovative Dermatology, Plano, TX, USA; [11]University of Texas Southwestern Medical Center, Dallas, TX, USA

BACKGROUND/OBJECTIVE

VISIBLE is an ongoing Phase 3b, multicenter, randomized, double-blinded, placebo (PBO)-controlled study of guselkumab (GUS) for the treatment of participants with moderate-to-severe plaque psoriasis (PsO) across all skin tones

VISIBLE is comprised of 2 cohorts:

Cohort A: participants with moderate-to-severe plaque PsO

Cohort B: participants with moderate-to-severe scalp PsO

VISIBLE evaluated the efficacy and safety of GUS in Cohort A participants through Week 48

CONCLUSIONS

**At Week 48, among GUS-randomized participants in Cohort A of the VISIBLE study:**

- >70% achieved clear/almost clear skin (IGA 0/1, PASI 90), and >50% achieved complete skin clearance (IGA 0, PASI 100)
- Mean percent improvement from baseline in BSA and PASI was ~95%
- Clinically meaningful improvements in the mean overall PSSD Symptoms Score and the mean PSSD Itch Symptom Score were achieved

No new safety signals were identified

These results demonstrate that GUS is a highly effective and durable treatment for moderate-to-severe plaque PsO in participants across all objectively measured skin tones, with sustained or improved responses through Week 48

METHODS

Included participants who self-identified as non-white, across all objectively measured skin tones

Cohort A: 103 participants with moderate-to-severe plaque PsO
BSA ≥10%, PASI ≥12, IGA ≥3

Cohort B: 108 participants with moderate-to-severe scalp PsO
SSA ≥30%, PSSI ≥12, ss-IGA ≥3, ≥1 plaque outside of the scalp

R (3:1)

GUS — GUS 100 mg at W0 and W4, then q8w to W100

PBO — W0, W4, W12

PBO→GUS — GUS 100 mg at W16 and W20, then q8w to W100

Week 0 | Week 16 *Primary endpoint analysis* | Week 48 *DBL for current analysis* | Week 112 *LTE (ongoing)*

BSA=body surface area; DBL=database lock; IGA=Investigator's Global Assessment; GUS=guselkumab; LTE=long-term extension; PASI=Psoriasis Area and Severity Index; PBO=placebo; PsO=plaque psoriasis; PSSI=Psoriasis Scalp Severity Index; q8w=every 8 weeks; R=randomized; SSA=scalp surface area; ss-IGA=Scalp-specific–Investigator's Global Assessment; W=week.

BASELINE CHARACTERISTICS

FST By Race/Ethnicity in Total Population (N=211)

Black (n=24); African American (n=18); American Indian or Alaska Native (n=1); Asian (n=63); East Asian (n=14); Filipino (n=7); South Asian (n=22); Southeast Asian (n=20); Non-white Hispanic/Latino (n=94); Central American (n=9); Cuban (n=13); Mexican (n=50); Puerto Rican (n=5); South American (n=15); Middle Eastern (n=13); Native Hawaiian or Pacific Islander (n=1); Multiracial (n=12); Other (n=3)

FST: II, III, IV, V, VI

FST=Fitzpatrick skin type.

Cohort A Demographics (N=103)

Male 72% | Mean Age 44.1 y | Mean Weight 209 lb | 31.1% FST I-III, 68.9% FST IV-VI

Cohort A Baseline Disease Characteristics

	PBO (N=26)	GUS (N=77)
PsO Duration, y	14.9 (8.8)	14.9 (11.0)
ss-IGA, n (%)		
Moderate (3)	21 (80.8)	57 (74.0)
Severe (4)	5 (19.2)	20 (26.0)
PSSI (0–72)	19.8 (6.2)	21.2 (9.9)
BSA, %	26.1 (15.9)	27.0 (20.4)
PSSD (0–100)	61.8 (27.0)	66.1 (25.0)

Data are presented as mean (standard deviation), unless otherwise specified. BSA=body surface area; GUS=guselkumab; PBO=placebo; PsO=plaque psoriasis; PSSD=Psoriasis Symptoms and Signs Diary; PSSI=Psoriasis Scalp Severity Index; ss-IGA=Scalp-specific–Investigator's Global Assessment.

RESULTS

Significantly greater proportions of GUS-randomized vs PBO-randomized participants achieved IGA and PASI endpoints at Week 16, and response rates were sustained or increased at Week 48

Proportion of Participants Achieving IGA 0/1 and PASI 90
74.0***; 57.1***; 3.8; 84.0; 76.6; 76.0; 70.1

Week 0: IGA 3, PASI 41.5, BSA 56%
Week 16: IGA 1, PASI 1.6, BSA 5%, ΔPASI 96.1%, ΔBSA 91.1%

Proportion of Participants Achieving IGA 0 and PASI 100
32.5***; 29.9**; 54.5; 54.5; 48.0; 44.0

Week 48: IGA 0, PASI 0, BSA 0%, ΔPASI 100%, ΔBSA 100%

IGA Responses: PBO (N=26); PBO→GUS (N=25)*; GUS (N=77)
PASI Responses: PBO (N=26); PBO→GUS (N=25)*; GUS (N=77)

**p<0.01 vs PBO; ***p<0.001 vs PBO; p-values were based on the Cochran-Mantel-Haenszel test stratified by FST (I-III/IV-VI). *For participants who were randomized to PBO at Week 0, only those who crossed over to GUS at or after Week 16 were included at Week 48. Participants who discontinued study agent due to lack of efficacy, worsening of PsO, or use of a prohibited PsO treatment prior to designated visit were considered non-responders from that point forward. Participants with missing data were considered non-responders at that time point. BSA=body surface area; FST=Fitzpatrick skin type; GUS=guselkumab; IGA=Investigator's Global Assessment; PASI=Psoriasis Area and Severity Index; PBO=placebo; PsO=plaque psoriasis; Δ=mean improvement.

Among GUS-randomized participants, mean percent improvement in BSA and PASI was >77% at Week 16 and increased to ~95% at Week 48

Mean Percent Improvement From Baseline in BSA
77.3***; -0.8; 94.4; 87.2

Week 0: IGA 3, PASI 20.1, BSA 23%
Week 16: IGA 0, PASI 0, BSA 0%, ΔPASI 100%, ΔBSA 100%

Mean Percent Improvement From Baseline in PASI
84.9***; 8.8; 94.9; 91.1

Week 48: IGA 0, PASI 0, BSA 0%, ΔPASI 100%, ΔBSA 100%

PBO: N=26 (25); GUS: N=77 (74), (70), (24)

***p<0.001 vs PBO; p-values were based on the mixed-effect model for repeated measures (MMRM). *For participants who were randomized to PBO at Week 0, only those who crossed over to GUS at or after Week 16 were included. When participants who discontinued study agent due to lack of efficacy, worsening of PsO, or use of a prohibited PsO treatment, 0 change from baseline was assigned from that point onward. Missing data were not imputed. BSA=body surface area; GUS=guselkumab; IGA=Investigator's Global Assessment; PASI=Psoriasis Area and Severity Index; PBO=placebo; PsO=plaque psoriasis; Δ=mean improvement.

Among GUS-randomized participants, the overall PSSD Symptoms Score and the PSSD Itch Symptom Score showed significant mean improvements from baseline at Week 16, which were maintained at Week 48

- The proportion of GUS-randomized participants achieving an overall PSSD Symptoms Score of 0[b] increased from 10% at Week 16 to 23% at Week 48, and the proportion achieving ≥4-point improvement from baseline in the PSSD Itch Symptom Score[c] was durable

Mean PSSD Symptoms Score
100 = Worst symptoms; CMI: ≥40-point change from BL; 0 = Symptom free
***; Δ_{BL}= 49.6; Δ_{BL}= 54.4
PBO: N=26 (25, 24); GUS: N=77 (75, 70)

Mean PSSD Itch Symptom Score
10 = Worst itch imaginable; CMI: ≥4-point change from BL; 0 = No itch
***; Δ_{BL}= 4.7; Δ_{BL}= 5.5
PBO: N=26 (25, 24); GUS: N=77 (75, 70)

PBO; PBO→GUS; GUS

***p<0.001 vs PBO; p-values were based on the MMRM. When participants discontinued study agent due to lack of efficacy, worsening of PsO, or use of a prohibited PsO treatment, 0 change from baseline was assigned from that point onward. Missing data were not imputed. *For participants who were randomized to PBO at Week 0, only those who crossed over to GUS at or after Week 16 were included. [b]GUS-randomized participants with baseline PSSD Symptoms Score ≥1. [c]Participants with baseline PSSD Itch Symptom Score ≥4. Participants who discontinued study agent due to lack of efficacy, worsening of PsO, or use of a prohibited PsO treatment prior to designated visit were considered non-responders from that point forward. Participants with missing data were considered non-responders at that time point. BL=baseline; CMI=clinically meaningful improvement; GUS=guselkumab; MMRM=mixed-effect model for repeated measures; PBO=placebo; PsO=plaque psoriasis; PSSD=Psoriasis Symptoms and Signs Diary; Δ_{BL}=mean improvement from baseline.

Key Safety Information

	PBO→GUS[d] (Weeks 16–48)	GUS (Weeks 0–48)
Safety analysis set, N	25	77
Average duration of follow-up (weeks)	31.5	46.3
Participants with ≥1 AE	5 (20.0)	48 (62.3)
Participants with ≥1 AE leading to discontinuation of study agent	0	2 (2.6)[e]
Participants with ≥1 SAE	1 (4.0)[f]	1 (1.3)[g]
Participants with ≥1 injection-site reaction	0	0
Infections	5 (20.0)	28 (36.4)
Serious infections	1 (4.0)[f]	1 (1.3)[g]

Data shown are n (%), unless otherwise indicated. [d]Includes only PBO participants who crossed over to receive GUS. [e]AEs leading to discontinuation among GUS-treated participants were 1 event each of pregnancy and impetiginized atopic dermatitis. [f]The SAE in a PBO→GUS participant was 1 event of cellulitis. [g]The SAE in a GUS-treated participant was 1 event of pyelonephritis. Participants were counted only once for any given event, regardless of the number of times they experienced the event. AEs were coded using MedDRA version 25.1. AE=adverse event; GUS=guselkumab; MedDRA=Medical Dictionary for Regulatory Activities; PBO=placebo; SAE=serious adverse event.

- Through Week 48, there were no cases of death, malignancy, active tuberculosis, major adverse cardiac event, inflammatory bowel disease, or serum-like sickness or anaphylaxis